---
type: "Nootropic"
title: "Acetyl-L-Carnitine"
description: "Acetyl-L-carnitine plays a role in energy metabolism. Cognitive and neuropathy research findings vary by condition; cognitive benefits in healthy young people remain uncertain."
resource: "https://nootropikler.com/nootropics/acetyl-l-carnitine"
tags: ["ALCAR", "Energy Metabolism"]
timestamp: 2026-11-11T00:00:00Z
category: "cognitive"
source: "semi-synthetic"
latin: "Acetyl-L-carnitine (ALCAR)"
language: "en"
---

# Acetyl-L-Carnitine

*Acetyl-L-carnitine (ALCAR)*

Acetyl-L-carnitine plays a role in energy metabolism. Cognitive and neuropathy research findings vary by condition; cognitive benefits in healthy young people remain uncertain.

## Quick profile

| Property | Value |
| --- | --- |
| Onset of Effect | No established timeframe |
| Dose used in research | Depends on the studied product and protocol |
| Safety | See detailed safety warnings |

> Correction · 2026-11-11. Alzheimer results, conflicting reviews and taxane neuropathy were separated. General-dose and unverified half-life fields, proven human-mechanism statements and unverified interaction statements were removed.

## What is Acetyl-L-Carnitine?

Acetyl-L-carnitine plays a role in energy metabolism. Cognitive and neuropathy research findings vary by condition; cognitive benefits in healthy young people remain uncertain.

## Mechanism of Effect

Most mechanism findings in this section come from cell or animal experiments; they do not establish the same effects or clinical benefits in humans.

## Clinical Evidence

Spagnoli et al. (1991) conducted a one-year placebo-controlled ALCAR trial in 130 people with Alzheimer's disease. Both groups declined, with slower deterioration on some tests in the ALCAR group.

Selected differences across multiple tests do not show that disease stopped or memory improved in healthy people. Read the result alongside later reviews.

Montgomery et al. (2003) pooled trials lasting 3–12 months in mild cognitive impairment or mild Alzheimer's disease. The integrated clinical and psychometric outcome showed a small difference favoring ALCAR over placebo (effect size 0.201).

This older analysis pooling different scales does not establish cognitive benefit in healthy young people or routine dementia treatment. The Cochrane assessment is more cautious.

Across 16 trials in the Cochrane review, some 24-week measures were positive, but benefit was not shown for dementia severity or functional ability. Positive findings may reflect multiple comparisons; routine clinical use was not recommended.

Populations and measures in this older review were heterogeneous; most analyses used trial completers. The findings are not a complete assessment of newer research or use in healthy people.

Di Stefano et al. (2019) systematically reviewed ALCAR research in painful peripheral neuropathy; this publication is not a randomized trial from 2000. Results cannot be treated as equivalent across different neuropathy causes.

## Dose information and research limits

> **Dose information and research limits:** This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

This comparison did not identify a suitable human plasma measurement validating the profile's general half-life; no numeric duration is used by the tool.

Controlled studies have not adequately established the efficacy and safety of these combinations in healthy people. Theoretical complementarity is not proven synergy or a recommendation to combine them.

## Safety and Side Effects

In a trial evaluating 409 women with breast cancer receiving taxanes, 3 g/day ALCAR did not prevent neuropathy at week 12; neuropathy was worse at week 24. Follow-up analysis also reported an adverse difference over two years.

This result concerns taxane chemotherapy and the studied ALCAR regimen; neuropathy types are not equivalent. It provides no basis for self-use to prevent neuropathy during chemotherapy.

In breast cancer patients receiving taxane chemotherapy, ALCAR did not prevent neuropathy and was associated with worse neuropathy in a randomized trial; the adverse difference persisted in long follow-up. Do not self-use it to prevent chemotherapy neuropathy; consult the oncology team.

NIH ODS notes that carnitine supplements can cause nausea, diarrhea and fishy body odor. A tolerable upper intake level has not been established for carnitine.

This carnitine-family summary does not determine ALCAR-specific adverse-effect rates or the magnitude of drug interactions. Absence of an upper limit does not mean unlimited safety.


## Frequently Asked Questions

### What does Acetyl-L-Carnitine (ALCAR) do?

Acetyl-L-carnitine plays a role in energy metabolism. Cognitive and neuropathy research findings vary by condition; cognitive benefits in healthy young people remain uncertain.

### What is the recommended daily dose for ALCAR?

This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

### When do the effects of Acetyl-L-Carnitine begin?

No established timeframe

### What are the side effects of ALCAR and is it safe?

In breast cancer patients receiving taxane chemotherapy, ALCAR did not prevent neuropathy and was associated with worse neuropathy in a randomized trial; the adverse difference persisted in long follow-up. Do not self-use it to prevent chemotherapy neuropathy; consult the oncology team.

### Is Acetyl-L-Carnitine legal in Türkiye and where can it be obtained?

Sale and import status in Türkiye must be checked for the specific product. Verify supplement approval in the Ministry of Agriculture and Forestry GGBS list, and medicine authorization and conditions of use in TİTCK records. Online availability does not establish approval or unrestricted personal import; current Ministry of Trade conditions apply to postal and express shipments.

## Sources

- Spagnoli A, et al. (1991). Long-term acetyl-L-carnitine treatment in Alzheimer's disease. *Neurology*, 41(11), 1726–1732. [PubMed · PMID 1944900](https://pubmed.ncbi.nlm.nih.gov/1944900/)
- Montgomery SA, et al. (2003). Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. *International Clinical Psychopharmacology*, 18(2), 61–71. [PubMed · PMID 12598816](https://pubmed.ncbi.nlm.nih.gov/12598816/)
- Ames BN, et al. (2004). Delaying the mitochondrial decay of aging with acetylcarnitine. *Annals of the New York Academy of Sciences*, 1033, 108–116. [PubMed · PMID 15591008](https://pubmed.ncbi.nlm.nih.gov/15591008/)
- Di Stefano G, et al. (2019). Acetyl-L-carnitine in painful peripheral neuropathy: a systematic review. *Journal of Pain Research*, 12, 1341–1351. https://doi.org/10.2147/JPR.S190231 [PubMed · PMID 31118753](https://pubmed.ncbi.nlm.nih.gov/31118753/)
- Bianchetti A, et al. (2003). Effects of acetyl-L-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors. *Current Medical Research and Opinion*, 19(4), 350–353. [PubMed · PMID 12841930](https://pubmed.ncbi.nlm.nih.gov/12841930/)
- Hershman DL, et al. (2013). Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. *Journal of Clinical Oncology*, 31(20), 2627–33. https://doi.org/10.1200/JCO.2012.44.8738 [PubMed · PMID 23733756](https://pubmed.ncbi.nlm.nih.gov/23733756/)
- Hershman DL, et al. (2018). Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715). *Journal of the National Cancer Institute*, 110(6), 669–676. https://doi.org/10.1093/jnci/djx259 [PubMed · PMID 29361042](https://pubmed.ncbi.nlm.nih.gov/29361042/)
- National Institutes of Health, Office of Dietary Supplements. Carnitine: Health Professional Fact Sheet. https://ods.od.nih.gov/factsheets/carnitine-healthprofessional/ [NIH Office of Dietary Supplements](https://ods.od.nih.gov/factsheets/carnitine-healthprofessional/)
- Hudson SA, Tabet N. (2003). Acetyl-L-carnitine for dementia. *Cochrane Database of Systematic Reviews*, (2), CD003158. [PubMed · PMID 12804452](https://pubmed.ncbi.nlm.nih.gov/12804452/)

## Related nootropics

- [Alpha-GPC](/okf/nootropics/alpha-gpc.md)
- [Creatine](/okf/nootropics/creatine.md)
- [Lion's Mane](/okf/nootropics/lions-mane.md)
